title: Effects of cefodizime on chemokines of liver tissues in mice with immunological hepatic injury.
abstract: BACKGROUND
  Chronic hepatic inflammation is characterized by the accumulation of lymphocytes as a consequence of increased recruitment from the blood and retention within the tissue at sites of infection. CXC chemokine ligand 16 (CXCL16) mRNA has been detected in both inflamed and normal liver tissues and is strongly upregulated in the injured liver tissues in a murine model. The aim of this study was to investigate the effect of cefodizime on CXCL16 mRNA of liver tissues in mice with immunological hepatic injury.
  
  
  METHODS
  The murine model of immunological hepatic injury was induced by Bacillus Calmette Guerin and Lipoposaccharide. The mice with immunological hepatic injury were randomly assigned to the model group, the cefodizime group and the ceftriaxone group. The three groups were continuously given agents for seven days and CXCL16 mRNA of liver tissue was determined and contrasted with the control group treated by normal saline. Reverse transcription-polymerase chain reaction was used to assay CXCL16 mRNA levels in liver tissues.
  
  
  RESULTS
  The expressions of CXCL16 mRNA were significantly higher in the model group and the ceftriaxone group than in the control group and the cefodizime group (P < 0.05), indicating the mice in the model group and the ceftriaxone group were immunodeficient. There was no statistical difference in the expressions of CXCL16 mRNA between the control group and the cefodizime group. Similarly, no statistical difference in the expressions of CXCL16 mRNA between the model group and the ceftriaxone group was detected (P > 0.05).
  
  
  CONCLUSIONS
  Cefodizime effectively reduces the infiltration of lymphocytes into liver tissues and alleviates the liver damage by decreasing CXCL16 mRNA in liver tissues in mice with immunological hepatic injury.
authors.affiliation: Clinical Pharmacology Base, First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan 450052, China.
authors.forename: Peng
authors.initials: P
authors.lastname: Wang
authors.forename: Quan-Cheng
authors.initials: QC
authors.lastname: Kan
authors.forename: Zu-Jiang
authors.initials: ZJ
authors.lastname: Yu
authors.forename: Ling
authors.initials: L
authors.lastname: Li
authors.forename: Xue
authors.initials: X
authors.lastname: Pan
mesh_terms: D000818:Animals; D002439:Cefotaxime / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000075743:Chemokine CXCL16; D054427:Chemokine CXCL6 / Q000235:genetics; D018925:Chemokines; D008070:Lipopolysaccharides / Q000633:toxicity; D008099:Liver / Q000187:drug effects* / Q000378:metabolism* / Q000382:microbiology; D051379:Mice; D009163:Mycobacterium bovis / Q000502:physiology; D012333:RNA, Messenger / Q000235:genetics; D020133:Reverse Transcriptase Polymerase Chain Reaction
chemical_list: D000075743:Chemokine CXCL16; D054427:Chemokine CXCL6; D018925:Chemokines; C498926:Cxcl16 protein, mouse; D008070:Lipopolysaccharides; D012333:RNA, Messenger; D002439:Cefotaxime; C033356:cefodizime